TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00296725
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
Study: NCT01925638
Drug: BAY86-9766
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02230878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo from Day 1 up to Day 10.
Study: NCT02746185
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
Study: NCT01521377
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single inhalation from GSK573719 500mcg DPI once daily
Study: NCT01521377
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Inhalation from matching Placebo DPI once daily
Study: NCT01604057
Drug: ZT-034 Mid Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray
Study: NCT01604057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray
Study: NCT01592032
Drug: Tigecycline antimicrobial-lock solution
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study: NCT01000727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered
Study: NCT04615702
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters.
Study: NCT00074282
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03448978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous cyclophosphamide
Study: NCT00783744
Drug: Insulin monotherapy with premixed insulin NPH 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
Study: NCT00920426
Drug: GSK1265744 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 30 mg
Study: NCT00920426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK1265744
Study: NCT00920426
Drug: GSK1265744 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 5mg
Study: NCT01292603
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1-3 or Days 1-5 of cycles 1-6
Study: NCT01759589
Drug: Remifentanil and propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
Study: NCT03303092
Drug: TEV-48125
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.
Study: NCT03303092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study: NCT01170117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group will receive placebo pill
Study: NCT01820728
Drug: Gonal-F®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02150473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo the same amount as adalimumab
Study: NCT02152670
Drug: Alpha Methyl Para Tyrosine (AMPT)
Normalized name: α-methyl-para-tyrosine
DrugBank: Metyrosine (DB00765)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00489606
Drug: SK3530
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03117166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
Study: NCT01605344
Drug: FOLFIRI.
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive FOLFIRI infusion on day 1 and day 15.
Study: NCT03031691
Drug: trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03320070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for SC injection
Study: NCT02041195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00621452
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01728753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
Study: NCT04543123
Drug: Antidepressant Drug(escitalopram)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
Study: NCT00286130
Drug: FOLFOX 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:
Study: NCT00286130
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Study: NCT01461668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two times a day for 5 days
Study: NCT01880424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching Placebo Capsules, Oral, once daily
Study: NCT00650091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo each day.
Study: NCT00502320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet at bedtime for up to 4 months
Study: NCT03558555
Drug: Acetaminophen IV Soln
Normalized name: acetaminophen Oral Solution
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg of IV acetaminophen
Study: NCT03558555
Drug: Oral Acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral acetaminophen 975mg pills
Study: NCT03558555
Drug: Placebo Pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo match to acetaminophen
Study: NCT04096326
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-151586 solution for injection.
Study: NCT04096326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for injection.
Study: NCT04390737
Drug: HH2853 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
Study: NCT03624101
Drug: symdeko/Trikafta
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR modulator
Study: NCT01106625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Study: NCT01106625
Drug: Sulphonylruea
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Study: NCT02652312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
Study: NCT00555048
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00555048
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00907153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth once daily for 12 weeks
Study: NCT01275625
Drug: HIV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
Study: NCT04706429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
Study: NCT01244347
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03119454
Drug: Diprospan
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular
Study: NCT00642746
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
Study: NCT00642746
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
Study: NCT01040208
Drug: placebo 2 tablets qhs
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg placebo
Study: NCT01634321
Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral suspension given once
Study: NCT00871949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed conditions, 600 mg oral suspension given once
Study: NCT00871949
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral suspension given once
Study: NCT00005612
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03008148
Drug: Siroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed.
Study: NCT04662242
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 100ml iv infusion for 7 days
Study: NCT00382980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
Study: NCT04536337
Drug: ALG-000184
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALG-000184
Study: NCT04536337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of Placebo
Study: NCT03887858
Drug: Harnal-D Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harnal-D Tab. 1T single oral administration under fasting
Study: NCT00375518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
Study: NCT01553643
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: at a rate of 3g two times per day
Study: NCT00535015
Drug: Betamarc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs BID
Study: NCT00717262
Drug: HQK-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
Study: NCT00717262
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered once a day, orally, for 14 days.
Study: NCT03212456
Drug: opioid-free group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
Study: NCT03212456
Drug: Opioid Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive fentanyl in the induction of anesthesia.
Study: NCT00826670
Drug: Placebo (Decolonization)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
Study: NCT03430817
Drug: Citicholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
Study: NCT04118114
Drug: PRL3-zumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration every 2 weeks
Study: NCT00972829
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 or 20 milligrams once or twice a week
Study: NCT00054249
Drug: T900607
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00620113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
Study: NCT02973516
Drug: P03277 at 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
Study: NCT02973516
Drug: P03277 at 0.05 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
Study: NCT04675996
Drug: INT-1B3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-min i.v. infusions twice per week in 21-day cycles
Study: NCT00376896
Drug: GW876008 200mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW876008
Study: NCT00376896
Drug: GW876008 20mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW876008 20mcg
Study: NCT03832010
Drug: Hydrocortisone Ointment
Normalized name: Hydrocortisone Ointment
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
Study: NCT02349295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03912259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution,~Route of administration: SC
Study: NCT00007189
Drug: Naproxen Sodium (Aleve)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00007189
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00791024
Drug: CRC-Pharma 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg
Study: NCT00440050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules twice a day for 18 months
Study: NCT02219087
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
Study: NCT02709473
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
Study: NCT00127075
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mcg, once a week
Study: NCT00127075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo treatments
Study: NCT00191074
Drug: somatropin, rDNA origin, for injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255086
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg placebo pill
Study: NCT00434122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day.
Study: NCT02170987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00717990
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Study: NCT04480294
Drug: HRS5091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose in group 1-5~Multiple doses in group 6-9
Study: NCT01963208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01892319
Drug: other injectable antidiabetic treatment regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician
Study: NCT03403725
Drug: MEN1309
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN1309 solution for intravenous infusion once every 3 weeks
Study: NCT02523820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
Study: NCT02207595
Drug: UCB5857
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use
Study: NCT04191577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00332800
Drug: Nutritional Supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02559206
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT02755844
Drug: metronomic cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
Study: NCT04193852
Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablets
Study: NCT04193852
Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablets
Study: NCT04447404
Drug: DUR-928
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04447404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04205578
Drug: Normal Saline 0.9% Infusion Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.